Top

BMC Cancer

Published in:

Open Access 01-12-2023 | Breast Cancer | Research

Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling

Authors: Rahma Melki, Marouane Melloul, Souria Aissaoui, Tijani EL Harroudi, Noureddine Boukhatem

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

Inherited mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 (BRCA1/2) confer high risks of breast and ovarian cancer. Because the contribution of BRCA1/2 germline mutations to BC in the Northeastern population of Morocco remains largely unknown, we conducted this first study to evaluate the prevalence and the phenotypic spectrum of two BRCA1/2 pathogenic mutations (the founder BRCA1 c.5309G>T and BRCA2 c.1310_1313delAAGA). This choice was also argued by the presence of an apparent specific geographical connection of these mutations and the Northeastern region of Morocco.

Methods

Screening for the germline mutations c.5309G>T and BRCA2 c.1310_1313delAAGA was performed by sequencing on a total of 184 breast cancer (BC) patients originated from the Northeastern region of Morocco.

The likelihood of identifying a BRCA mutation is calculated using the Eisinger scoring model. The clinical and pathologic features were compared between the BRCA-positive and BRCA-negative groups of patients. Difference in survival outcomes was compared between mutation carriers and non-carriers.

Results

BRCA1 c.5309G>T and BRCA2 c.1310_1313delAAGA are responsible for a significant proportion of all BC cases (12.5%) and at least 20% of familial BC. The screening of BRCA1/2 genes by NGS sequencing confirmed that there are no additional mutations detected among positive patients.

The clinicopathological features in positive patients were in accordance with typical characteristics of BRCA pathogenic mutations. The mean features in the carriers were the early onset of the disease, familial history, triple negative status (for BRCA1 c.5309G>T) and worse prognosis in terms of overall surviving.

Our study indicates that the Eisinger scoring model could be recommended to identify patients for referral to BRCA1/2 oncogenetic counseling.

Conclusion

Our findings suggest that BRCA1 c.5309G>T and BRCA2 c.1310_1313delAAGA mutations may have a strong founder and/or recurrent effect on breast cancer among the Northeastern Moroccan population. There contribution to breast cancer incidence is certainly substantial in this subgroup. Therefore, we believe that BRCA1 c.5309G>T and BRCA2 c.1310_1313delAAGA mutations have to be included in the array of tests aimed at revealing cancer syndrome carriers among subjects of Moroccan origin.

Mahdavi M, Nassiri M, Kooshyar MM, Vakili-Azghandi M, Avan A, Sandry R, et al. Hereditary breast cancer; genetic penetrance and current status with BRCA. J Cell Physiol. 2019;234(5):5741–50. https://doi.org/10.1002/jcp.27464.CrossRefPubMed

Monteiro AN, Bouwman P, Kousholt AN, Eccles DM, Millot GA, Masson JY, et al. Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation. J Med Genet. 2020;57(8):509–18. https://doi.org/10.1136/jmedgenet-2019-106368.CrossRefPubMed

Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402–16. https://doi.org/10.1001/jama.2017.7112.CrossRefPubMed

Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer. 2004;4(9):665–76. https://doi.org/10.1038/nrc1431.CrossRefPubMed

Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171–82. https://doi.org/10.1016/s0092-8674(02)00615-3.CrossRefPubMed

Gordon OK. Cancer of the Breast and Female Reproductive Tract. David Rimoin RPaBK, editor. Emery and Rimoin's Principles and Practice of Medical Genetics (Sixth Edition). Academic Press. Elsevier Science & Technology; 2013. p. 1–31. https://doi.org/10.1016/B978-0-12-383834-6.00093-8.

Laitman Y, Feng BJ, Zamir IM, Weitzel JN, Duncan P, Port D, et al. Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. Eur J Hum Genet. 2013;21(2):212–6. https://doi.org/10.1038/ejhg.2012.124.CrossRefPubMed

Ferla R, Calo V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, et al. Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol. 2007;18(Suppl 6):vi93-8. https://doi.org/10.1093/annonc/mdm234.CrossRefPubMed

Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, et al. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. J Natl Compr Canc Netw. 2016;14(2):153–62. https://doi.org/10.6004/jnccn.2016.0018.CrossRefPubMed

10.

Lee A, Moon BI, Kim TH. BRCA1/BRCA2 pathogenic variant breast cancer: treatment and prevention strategies. Ann Lab Med. 2020;40(2):114–21. https://doi.org/10.3343/alm.2020.40.2.114.CrossRefPubMed

11.

Rotimi SO, Rotimi OA, Salhia B. A review of cancer genetics and genomics studies in Africa. Front Oncol. 2020;10:606400. https://doi.org/10.3389/fonc.2020.606400.CrossRefPubMed

12.

Fondation Lalla Salma Prévention et traitement des Cancers. Prévention et traitement des Cancers. Registre des cancers de la région du Grand Casablanca pour la période 2008–2012. 2016.

13.

Hashim MJ, Al-Shamsi FA, Al-Marzooqi NA, Al-Qasemi SS, Mokdad AH, Khan G. Burden of breast cancer in the Arab World: findings from Global Burden of Disease, 2016. J Epidemiol Glob Health. 2018;8(1–2):54–8. https://doi.org/10.2991/j.jegh.2018.09.003.CrossRefPubMedPubMedCentral

14.

Mrabti H, Sauvaget C, Benider A, Bendahhou K, Selmouni F, Muwonge R, et al. Patterns of care of breast cancer patients in Morocco - A study of variations in patient profile, tumour characteristics and standard of care over a decade. Breast. 2021;59:193–202. https://doi.org/10.1016/j.breast.2021.07.009.CrossRefPubMedPubMedCentral

15.

Tazzite A, Jouhadi H, Saiss K, Benider A, Nadifi S. Relationship between family history of breast cancer and clinicopathological features in Moroccan patients. Ethiop J Health Sci. 2013;23(2):150–7.PubMedPubMedCentral

16.

Laarabi FZ, Jaouad IC, Ouldim K, Aboussair N, Jalil A, Gueddari BE, et al. Genetic testing and first presymptomatic diagnosis in Moroccan families at high risk for breast/ovarian cancer. Oncol Lett. 2011;2(2):389–93. https://doi.org/10.3892/ol.2011.248.CrossRefPubMedPubMedCentral

17.

Tazzite A, Jouhadi H, Nadifi S, Aretini P, Falaschi E, Collavoli A, et al. BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants. Gynecol Oncol. 2012;125(3):687–92. https://doi.org/10.1016/j.ygyno.2012.03.007.CrossRefPubMed

18.

Laraqui A, Uhrhammer N, Lahlou-Amine I, El Rhaffouli H, El Baghdadi J, Dehayni M, et al. Mutation screening of the BRCA1 gene in early onset and familial breast/ovarian cancer in Moroccan population. Int J Med Sci. 2013;10(1):60–7. https://doi.org/10.7150/ijms.5014.CrossRefPubMed

19.

Bakkach J, Mansouri M, Derkaoui T, Loudiyi A, El Fahime E, Barakat A, et al. Contribution of BRCA1 and BRCA2 germline mutations to early onset breast cancer: a series from north of Morocco. BMC Cancer. 2020;20(1):859. https://doi.org/10.1186/s12885-020-07352-9.CrossRefPubMedPubMedCentral

20.

Guaoua S, Ratbi I, Lyahyai J, El Alaoui SC, Laarabi FZ, Sefiani A. Novel nonsense mutation of BRCA2 gene in a Moroccan man with familial breast cancer. Afr Health Sci. 2014;14(2):468–71. https://doi.org/10.4314/ahs.v14i2.25.CrossRefPubMedPubMedCentral

21.

El Ansari FZ, Jouali F, Marchoudi N, Bennani MM, Ghailani NN, Barakat A, et al. Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC). BMC Cancer. 2020;20(1):747. https://doi.org/10.1186/s12885-020-07250-0.CrossRefPubMedPubMedCentral

22.

Quiles F, Teule A, Martinussen Tandstad N, Feliubadalo L, Tornero E, Del Valle J, et al. Identification of a founder BRCA1 mutation in the Moroccan population. Clin Genet. 2016;90(4):361–5. https://doi.org/10.1111/cge.12747.CrossRefPubMed

23.

Jouali F, Laarabi FZ, Marchoudi N, Ratbi I, Elalaoui SC, Rhaissi H, et al. First application of next-generation sequencing in Moroccan breast/ovarian cancer families and report of a novel frameshift mutation of the BRCA1 gene. Oncol Lett. 2016;12(2):1192–6. https://doi.org/10.3892/ol.2016.4739.CrossRefPubMedPubMedCentral

24.

Laarabi FZ, Ratbi I, Elalaoui SC, Mezzouar L, Doubaj Y, Bouguenouch L, et al. High frequency of the recurrent c.1310_1313delAAGA BRCA2 mutation in the North-East of Morocco and implication for hereditary breast-ovarian cancer prevention and control. BMC Res Notes. 2017;10(1):188. https://doi.org/10.1186/s13104-017-2511-2.CrossRefPubMedPubMedCentral

25.

Dutil J, Colon-Colon JL, Matta JL, Sutphen R, Echenique M. Identification of the prevalent BRCA1 and BRCA2 mutations in the female population of Puerto Rico. Cancer Genet. 2012;205(5):242–8. https://doi.org/10.1016/j.cancergen.2012.04.002.CrossRefPubMedPubMedCentral

26.

Eisinger F, Bressac B, Castaigne D, Cottu PH, Lansac J, Lefranc JP, et al. Identification and management of hereditary breast/ovarian cancers (2004 update). La Lettre du Gynécologue. 2004;294:26–37.

27.

Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215. https://doi.org/10.1093/nar/16.3.1215.CrossRefPubMedPubMedCentral

28.

Untergasser A, Cutcutache I, koressaar T, Ye J, Faircloth BC, Remm M, et al. Primer3 - new capabilities and interfaces. 2012.CrossRef

29.

Grindedal EM, Heramb C, Karsrud I, Ariansen SL, Maehle L, Undlien DE, et al. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers. BMC Cancer. 2017;17(1):438. https://doi.org/10.1186/s12885-017-3422-2.CrossRefPubMedPubMedCentral

30.

Heramb C, Wangensteen T, Grindedal EM, Ariansen SL, Lothe S, Heimdal KR, et al. BRCA1 and BRCA2 mutation spectrum - an update on mutation distribution in a large cancer genetics clinic in Norway. Hered Cancer Clin Pract. 2018;16:3. https://doi.org/10.1186/s13053-017-0085-6.CrossRefPubMedPubMedCentral

31.

Mansouri M, Derkaoui T, Bakkach J, Loudiyi A, Ghailani Nourouti N, Barakat A, et al. Screening of BRCA1 and BRCA2 germline mutations in unselected triple-negative breast cancer patients: A series from north of Morocco. Precis Med Sci. 2020;9:43–8. https://doi.org/10.1002/prm2.12009.CrossRef

32.

Tudini E, Moghadasi S, Parsons MT, van der Kolk L, van den Ouweland AMW, Niederacher D, et al. Substantial evidence for the clinical significance of missense variant BRCA1 c.5309G>T p.(Gly1770Val). Breast Cancer Res Treat. 2018;172(2):497–503. https://doi.org/10.1007/s10549-018-4903-y.CrossRefPubMed

33.

Bouwman P, van der Gulden H, van der Heijden I, Drost R, Klijn CN, Prasetyanti P, et al. A high-throughput functional complementation assay for classification of BRCA1 missense variants. Cancer Discov. 2013;3(10):1142–55. https://doi.org/10.1158/2159-8290.CD-13-0094.CrossRefPubMed

34.

Quiles F, Fernandez-Rodriguez J, Mosca R, Feliubadalo L, Tornero E, Brunet J, et al. Functional and structural analysis of C-terminal BRCA1 missense variants. PLoS One. 2013;8(4):e61302. https://doi.org/10.1371/journal.pone.0061302.CrossRefPubMedPubMedCentral

35.

Cherbal F, Bakour R, Adane S, Boualga K, Benais-Pont G, Maillet P. BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families. Dis Markers. 2010;28(6):377–84. https://doi.org/10.3233/DMA-2010-0718.CrossRefPubMedPubMedCentral

36.

Fourati A, Louchez MM, Fournier J, Gamoudi A, Rahal K, El May MV, et al. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer. Bull Cancer. 2014;101(11):E36-40. https://doi.org/10.1684/bdc.2014.2049.CrossRefPubMed

37.

Ben Ayed-Guerfali D, Ben Kridis-Rejab W, Ammous-Boukhris N, Ayadi W, Charfi S, Khanfir A, et al. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia. J Transl Med. 2021;19(1):108. https://doi.org/10.1186/s12967-021-02772-y.CrossRefPubMedPubMedCentral

38.

Caputo S, Benboudjema L, Sinilnikova O, Rouleau E, Beroud C, Lidereau R, et al. Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. Nucleic Acids Res. 2012;40(Database issue):D992-1002. https://doi.org/10.1093/nar/gkr1160.CrossRefPubMed

39.

Meisel C, Sadowski CE, Kohlstedt D, Keller K, Staritz F, Grubling N, et al. Spectrum of genetic variants of BRCA1 and BRCA2 in a German single center study. Arch Gynecol Obstet. 2017;295(5):1227–38. https://doi.org/10.1007/s00404-017-4330-z.CrossRefPubMed

40.

Tea MK, Kroiss R, Muhr D, Fuerhauser-Rappaport C, Oefner P, Wagner TM, et al. Central European BRCA2 mutation carriers: birth cohort status correlates with onset of breast cancer. Maturitas. 2014;77(1):68–72. https://doi.org/10.1016/j.maturitas.2013.09.012.CrossRefPubMed

41.

Vos JR, Teixeira N, van der Kolk DM, Mourits MJ, Rookus MA, van Leeuwen FE, et al. Variation in mutation spectrum partly explains regional differences in the breast cancer risk of female BRCA mutation carriers in the Netherlands. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2482–91. https://doi.org/10.1158/1055-9965.EPI-13-1279.CrossRefPubMed

42.

Wojcik P, Jasiowka M, Strycharz E, Sobol M, Hodorowicz-Zaniewska D, Skotnicki P, et al. Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland. Hered Cancer Clin Pract. 2016;14:5. https://doi.org/10.1186/s13053-016-0046-5.CrossRefPubMedPubMedCentral

43.

Cruz-Correa M, Perez-Mayoral J, Dutil J, Echenique M, Mosquera R, Rivera-Roman K, et al. Hereditary cancer syndromes in Latino populations: genetic characterization and surveillance guidelines. Hered Cancer Clin Pract. 2017;15:3. https://doi.org/10.1186/s13053-017-0063-z.CrossRefPubMedPubMedCentral

44.

El Saghir NS, Zgheib NK, Assi HA, Khoury KE, Bidet Y, Jaber SM, et al. BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer. Oncologist. 2015;20(4):357–64. https://doi.org/10.1634/theoncologist.2014-0364.CrossRefPubMedPubMedCentral

45.

Donenberg T, Ahmed H, Royer R, Zhang S, Narod SA, George S, et al. A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago. Breast Cancer Res Treat. 2016;159(1):131–8. https://doi.org/10.1007/s10549-016-3870-4.CrossRefPubMed

46.

Gayther SA, Russell P, Harrington P, Antoniou AC, Easton DF, Ponder BA. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet. 1999;65(4):1021–9. https://doi.org/10.1086/302583.CrossRefPubMedPubMedCentral

47.

Maillet P, Chappuis PO, Khoshbeen-Boudal M, Sciretta V, Sappino AP, Testing SNfCP, et al. Twenty-three novel BRCA1 and BRCA2 sequence variations identified in a cohort of Swiss breast and ovarian cancer families. Cancer Genet Cytogenet. 2006;169(1):62–8. https://doi.org/10.1016/j.cancergencyto.2006.03.010.CrossRefPubMed

48.

Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016;18(1):15. https://doi.org/10.1186/s13058-016-0671-y.CrossRefPubMedPubMedCentral

49.

Bonaiti B, Alarcon F, Bonadona V, Pennec S, Andrieu N, Stoppa-Lyonnet D, et al. A new scoring system for the diagnosis of BRCA1/2 associated breast-ovarian cancer predisposition. Bull Cancer. 2011;98(7):779–95. https://doi.org/10.1684/bdc.2011.1397.CrossRefPubMed

50.

Deng M, Chen HH, Zhu X, Luo M, Zhang K, Xu CJ, et al. Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China. Int J Cancer. 2019;145(6):1517–28. https://doi.org/10.1002/ijc.32184.CrossRefPubMed

Title: Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling
Authors: Rahma Melki
Marouane Melloul
Souria Aissaoui
Tijani EL Harroudi
Noureddine Boukhatem
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-10822-5

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Association of immune-related adverse events with COVID-19 pneumonia in lung cancer patients receiving immune checkpoint inhibitors: a cross-sectional study in China

HOXA9 gene promotor methylation and copy number variation of SOX2 and HV2 genes in cell free DNA: A potential diagnostic panel for non-small cell lung cancer

The potential of PARP as a therapeutic target across pediatric solid malignancies

The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial

Lactate dehydrogenase D serves as a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma